SHALETA INGRAM: Open Payments
NPI 1710519277 · LUFKIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 27 payments from 9 companies in 2025. Trend: 2023 $1,395 · 2024 $1,263 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $149 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $77 |
| Dexcom, Inc. | 3 | $68 |
| PFIZER INC. | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
| ABBVIE INC. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
Products named: Ozempic, Kerendia, Dexcom G6 Transmitter, ELIQUIS, BREZTRI, Quviviq, Rybelsus, UBRELVY.
Industry payments across TX — which companies pay providers there.
